Simvastatin induces a central hypotensive effect via Ras-mediated signalling to cause eNOS up-regulation

British Journal of Pharmacology

Volumn 170, Issue 4, 2013, Pages 847-858

  Cheng, Wen Han ^a,b   Ho, Wen Yu ^c,d   Chang, Chien Feng ^e   Lu, Pei Jung ^f   Cheng, Pei Wen ^a   Yeh, Tung Chen ^a   Hong, Ling Zong ^g   Sun, Gwo Ching ^h   Hsiao, Michael ⁱ   Tseng, Ching Jiunn ^a,b,e,j  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^g TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^h YULI VETERANS HOSPITAL   (Taiwan)

ⁱ GENOMICS RESEARCH CENTER   (Taiwan)

^j NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

more..

Author keywords

hypertension; isoprenylation; nitric oxide; nucleus tractus solitarii; Ras; statins

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GERANYLGERANYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; RAC1 PROTEIN; RAS PROTEIN; S6 KINASE; SIMVASTATIN; TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL SYMPATHETIC NERVE ACTIVITY; SIGNAL TRANSDUCTION; SOLITARY TRACT NUCLEUS; SPONTANEOUSLY HYPERTENSIVE RAT; SYMPATHETIC NERVE; UPREGULATION;

HYPERTENSION; ISOPRENYLATION; NITRIC OXIDE; NUCLEUS TRACTUS SOLITARII; RAS; STATINS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HYPERTENSION; KIDNEY; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RAC1 GTP-BINDING PROTEIN; RAS PROTEINS; RATS; RATS, INBRED SHR; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SIMVASTATIN; SOLITARY NUCLEUS; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS;

EID: 84885146950     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12317     Document Type: Article

References (57)

1. Bezerra DG, Mandarim-de-Lacerda CA, (2005). Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats. Clin Sci (Lond) 108: 349-355.
2. Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A, Brisighella Heart Study Working P (2004). Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 148: 285-292.
3. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM, (2007). Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 8: 766-775.
4. Cheng PW, Wu AT, Lu PJ, Yang YC, Ho WY, Lin HC, et al. (2012a). Central hypotensive effects of neuropeptide Y are modulated by endothelial nitric oxide synthase after activation by ribosomal protein S6 kinase. Br J Pharmacol 167: 1148-1160.
5. Cheng WH, Lu PJ, Ho WY, Tung CS, Cheng PW, Hsiao M, et al. (2010). Angiotensin II inhibits neuronal nitric oxide synthase activation through the ERK1/2-RSK signaling pathway to modulate central control of blood pressure. Circ Res 106: 788-795.
6. Cheng WH, Lu PJ, Hsiao M, Hsiao CH, Ho WY, Cheng PW, et al. (2012b). Renin activates PI3K-Akt-eNOS signalling through the angiotensin AT(1) and Mas receptors to modulate central blood pressure control in the nucleus tractus solitarii. Br J Pharmacol 166: 2024-2035.
7. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, et al. (2002). Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 39: 1020-1025.
8. Gao L, Wang W, Zucker IH, (2008). Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J Pharmacol Exp Ther 326: 278-285.
9. Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K, (2009). Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 29: 13543-13556.
10. Goldstein JL, Brown MS, (1990). Regulation of the mevalonate pathway. Nature 343: 425-430.
11. Guyenet PG, (2006). The sympathetic control of blood pressure. Nat Rev Neurosci 7: 335-346.
12. Halcox JP, Deanfield JE, (2004). Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109: II42-II48.
13. Hirooka Y, (2008). Role of reactive oxygen species in brainstem in neural mechanisms of hypertension. Auton Neurosci 142: 20-24.
14. Ho WY, Lu PJ, Hsiao M, Hwang HR, Tseng YC, Yen MH, et al. (2008). Adenosine modulates cardiovascular functions through activation of extracellular signal-regulated kinases 1 and 2 and endothelial nitric oxide synthase in the nucleus tractus solitarii of rats. Circulation 117: 773-780.
15. Huang HN, Lu PJ, Lo WC, Lin CH, Hsiao M, Tseng CJ, (2004). In situ Akt phosphorylation in the nucleus tractus solitarii is involved in central control of blood pressure and heart rate. Circulation 110: 2476-2483.
16. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, et al. (1998). Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 98: 211-216.
17. John S, Delles C, Jacobi J, Schlaich MP, Schneider M, Schmitz G, et al. (2001). Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 37: 1351-1358.
18. Kanbay M, Yildirir A, Bozbas H, Ulus T, Bilgi M, Muderrisoglu H, et al. (2005). Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren Fail 27: 297-303.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
20. Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A, (2003). Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 21: 379-386.
21. Kishi T, Hirooka Y, Kimura Y, Ito K, Shimokawa H, Takeshita A, (2004). Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 109: 2357-2362.
22. Kishi T, Hirooka Y, Shimokawa H, Takeshita A, Sunagawa K, (2008). Atorvastatin reduces oxidative stress in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 30: 3-11.
23. Kishi T, Hirooka Y, Konno S, Sunagawa K, (2010). Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 55: 184-190.
24. Koh KK, Quon MJ, Waclawiw MA, (2008). Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis 196: 1-8.
25. Kou R, Sartoretto J, Michel T, (2009). Regulation of Rac1 by simvastatin in endothelial cells: differential roles of AMP-activated protein kinase and calmodulin-dependent kinase kinase-β. J Biol Chem 284: 14734-14743.
26. Kubota Y, Umegaki K, Kagota S, Tanaka N, Nakamura K, Kunitomo M, et al. (2006). Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharm Bull 29: 1756-1758.
27. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. (2000). The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010.
28. Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, et al. (2000a). Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 102: 3104-3110.
29. Laufs U, Endres M, Stagliano N, Amin-Hanjani S, Chui DS, Yang SX, et al. (2000b). Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 106: 15-24.
30. Levine YC, Li GK, Michel T, (2007). Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells: evidence for an AMPK → Rac1 → Akt → endothelial nitric-oxide synthase pathway. J Biol Chem 282: 20351-20364.
31. Lewandowski J, Sinski M, Bidiuk J, Abramczyk P, Dobosiewicz A, Ciarka A, et al. (2010). Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertens Res 33: 1038-1043.
32. Liao JK, (2002). Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110: 285-288.
33. Liu YJ, Wang XG, Tang YB, Chen JH, Lv XF, Zhou JG, et al. (2010). Simvastatin ameliorates rat cerebrovascular remodeling during hypertension via inhibition of volume-regulated chloride channel. Hypertension 56: 445-452.
34. Lorkowska B, Bartus M, Franczyk M, Kostogrys RB, Jawien J, Pisulewski PM, et al. (2006). Hypercholesterolemia does not alter endothelial function in spontaneously hypertensive rats. J Pharmacol Exp Ther 317: 1019-1026.
35. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
36. McTaggart SJ, (2006). Isoprenylated proteins. Cell Mol Life Sci 63: 255-267.
37. Maurer-Stroh S, Washietl S, Eisenhaber F, (2003). Protein prenyltransferases. Genome Biol 4: 212-220.
38. Merla R, Ye Y, Lin Y, Manickavasagam S, Huang MH, Perez-Polo RJ, et al. (2007). The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol 293: H1918-H1928.
39. Nozoe M, Hirooka Y, Koga Y, Sagara Y, Kishi T, Engelhardt JF, et al. (2007). Inhibition of Rac1-derived reactive oxygen species in nucleus tractus solitarius decreases blood pressure and heart rate in stroke-prone spontaneously hypertensive rats. Hypertension 50: 62-68.
40. Ohkawara H, Ishibashi T, Saitoh S, Inoue N, Sugimoto K, Kamioka M, et al. (2010). Preventive effects of pravastatin on thrombin-triggered vascular responses via Akt/eNOS and RhoA/Rac1 pathways in vivo. Cardiovasc Res 88: 492-501.
41. Paravicini TM, Touyz RM, (2006). Redox signaling in hypertension. Cardiovasc Res 71: 247-258.
42. Ramirez C, Tercero I, Pineda A, Burgos JS, (2011). Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. J Alzheimers Dis 24: 161-174.
43. Sabbatini M, Pisani A, Uccello F, Serio V, Seru R, Paterno R, et al. (2004). Atorvastatin improves the course of ischemic acute renal failure in aging rats. J Am Soc Nephrol 15: 901-909.
44. Sakai K, Hirooka Y, Matsuo I, Eshima K, Shigematsu H, Shimokawa H, et al. (2000). Overexpression of eNOS in NTS causes hypotension and bradycardia in vivo. Hypertension 36: 1023-1028.
45. Samuel F, Hynds DL, (2010). RHO GTPase signaling for axon extension: is prenylation important? Mol Neurobiol 42: 133-142.
46. Serajuddin AT, Ranadive SA, Mahoney EM, (1991). Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 80: 830-834.
47. Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS, (2011). Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 23: 307-318.
48. Sun W, Lee T-S, Zhu M, Gu C, Wang Y, Zhu Y, et al. (2006). Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 114: 2655-2662.
49. Tai MH, Hsiao M, Chan JY, Lo WC, Wang FS, Liu GS, et al. (2004). Gene delivery of endothelial nitric oxide synthase into nucleus tractus solitarii induces biphasic response in cardiovascular functions of hypertensive rats. Am J Hypertens 17: 63-70.
50. Takayama N, Kai H, Kudo H, Yasuoka S, Mori T, Anegawa T, et al. (2011). Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways. Hypertens Res 34: 341-347.
51. Terzoli L, Mircoli L, Raco R, Ferrari AU, (2005). Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 46: 310-315.
52. Tseng CJ, Liu HY, Lin HC, Ger LP, Tung CS, Yen MH, (1996). Cardiovascular effects of nitric oxide in the brain stem nuclei of rats. Hypertension 27: 36-42.
53. Van Aelst L, D'Souza-Schorey C, (1997). Rho GTPases and signaling networks. Genes Dev 11: 2295-2322.
54. Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, Dhayat S, et al. (2007). Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 50: 1977-1986.
55. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. (2001). HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37: 1450-1457.
56. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, et al. (1997). K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272: 14459-14464.
57. Yamauchi J, Miyamoto Y, Tanoue A, Shooter EM, Chan JR, (2005). Ras activation of a Rac1 exchange factor, Tiam1, mediates neurotrophin-3-induced Schwann cell migration. Proc Natl Acad Sci U S A 102: 14889-14894.